OR WAIT null SECS
© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Javier L. Munoz, MD, MS, FACP, explains the treatment options for relapsed/refractory follicular lymphoma and provides insight into a recent clinical trial.
July 6th 2021
Javier L. Munoz, MD, MS, FACP, describes the effects of R/R FL and discusses the current treatment options available.
A specialist explains the factors considered when it comes to choosing treatments for patients with relapsed/refractory follicular lymphoma, and the clinical endpoints to look for.
July 13th 2021
Javier L. Munoz, MD, MS, FACP, describes the current third-line treatment options available for relapsed/refractory follicular lymphoma.
An expert in relapsed/refractory follicular lymphoma discusses the approval of tazemetostat as a treatment and reviews the phase 2 clinical trial data.
July 20th 2021
Javier L. Munoz, MD, MS, FACP, discusses how the sequencing of therapies has changed in the last year.